| Literature DB >> 24130888 |
Gunlög Rasmussen1, Stefan Monecke, Ralf Ehricht, Bo Söderquist.
Abstract
Staphylococcus aureus encodes a remarkable number of virulence factors which may contribute to its pathogenicity and ability to cause invasive disease. The main objective of this study was to evaluate the association between S. aureus invasiveness and bacterial genotype, in terms of the presence of virulence genes and affiliation to clonal complexes. Also, the significance of different virulence genes, mainly adhesins, for the development of infective endocarditis was investigated. DNA microarray technology was used to analyze 134 S. aureus isolates, all methicillin-susceptible, derived from three groups of clinically well-characterized patients: nasal carriers (n=46), bacteremia (n=55), and bacteremia with infective endocarditis (n=33). Invasive isolates were dominant in four of the major clonal complexes: 5, 8, 15, and 25. Of the 170 virulence genes examined, those encoding accessory gene regulator group II (agr II), capsule polysaccharide serotype 5 (cap5), and adhesins such as S. aureus surface protein G (sasG) and fibronectin-binding protein B (fnbB) were found to be associated with invasive disease. The same was shown for the leukocidin genes lukD/lukE, as well as the genes encoding serine protease A and B (splA/splB), staphylococcal complement inhibitor (scn) and the staphylococcal exotoxin-like protein (setC or selX). In addition, there was a trend of higher prevalence of certain genes or gene clusters (sasG, agr II, cap5) among isolates causing infective endocarditis compared to other invasive isolates. In most cases, the presence of virulence genes was linked to clonal complex affiliation. In conclusion, certain S. aureus clonal lineages harboring specific sets of virulence genes seem to be more successful in causing invasive disease.Entities:
Mesh:
Substances:
Year: 2013 PMID: 24130888 PMCID: PMC3793971 DOI: 10.1371/journal.pone.0077477
Source DB: PubMed Journal: PLoS One ISSN: 1932-6203 Impact factor: 3.240
Characteristics of patients with S. aureus bacteremia with or without IE.
|
|
|
|
|
|---|---|---|---|
| Median age | 56 (range 24-91) | 66 (range 10-91) | 63 (range 10-91) |
| Sex (male) | 18 (55) | 34 (62) | 52 (59) |
| Patients with ≥2 blood cultures positive for | 31 (94) | 47 (85) | 78 (89) |
| Immunosuppression[ | 3 (9) | 5 (9) | 8 (9) |
| Diabetes mellitus[ | 2 (6) | 9 (16) | 11 (13) |
| Malignant disease | 2 (6) | 7 (13) | 9 (10) |
| IV drug abuse | 12 (36) | 1 (2) | 13 (15) |
| Indwelling devices[ | 8 (24) | 12 (22) | 20 (23) |
| Hematogenous complications[ | 33 (100) | 25 (45) | 58 (66) |
| Acute osteomyelitis | 1 (3) | 14 (25) | 15 (17) |
| Acute septic arthritis | 6 (18) | 9 (16) | 15 (17) |
| Meningitis | 1 (3) | 2 (4) | 3 (3) |
| Other CNS embolization | 5 (15) | 0 (0) | 5 (6) |
| Mortality[ | 3 (9) | 3 (5) | 6 (7) |
Treatment with corticosteroids, chemotherapy or immunosuppression due to leukemia
Treated with insulin or oral antidiabetics
Prescence of central venous catheter (n=2), pacemaker, cardiac valves, prosthetic joint devices or osteosynthesis material
IE, acute osteomyelitis, septic arthritis, deep seated abscesses or meningitis
Within 12 weeks after the initial positive blood culture
Distribution of CCs and ST.
|
|
|
|
|
|
|
|---|---|---|---|---|---|
| 5 | 112 | 1 (9) | 10 (91) | 3.0 (1.3-6.9)3 | 0.0123 |
| 8 | 9 | 2 (22) | 7 (78) | ||
| 15 | 15 | 3 (20) | 12 (80) | ||
| 25 | 11 | 3 (27) | 8 (73) | ||
| 30 | 31 | 18 (58) | 13 (42) | 0.25 (0.11-0.57) |
|
| 45 | 36 | 14 (39) | 22 (61) | 0.72 (0.32-1.6) | 0.42 |
| other[ | 21 | 5 (24) | 16 (76) | na | na |
| Total | 134 | 46 (34) | 88 (66) |
Fisher’s exact test
7/11 isolates originated from patients with IE
Counted on CCS 5, 8, 15 and 25 together
ST34, CC1, CC9, CC12, CC20, CC22, ST49, CC50, CC59, CC97, CC182, CC395 na; not applicable
Bold figures; statistically significant
Distribution of agr groups.
|
|
|
|
|
|
|
|---|---|---|---|---|---|
| I2 | 62 (46) | 21 (46) | 41 (47) | 1.0 (0.51-2.1) | 1 |
| II[ | 31 (23) | 5 (11) | 26 (30) | 3.4 (1.2-9.7) |
|
| III[ | 35 (26) | 18 (39) | 17 (19) | 0.37 (0.17-0.82) |
|
| IV[ | 6 (4) | 2 (4) | 4 (5) | 1.0 (0.19-5.9) | 1 |
Fisher’s exact test
CC8, CC20, CC22, CC25, CC45 (except CC45 agr IV), CC59, CC97, CC182, ST 426
CC5, CC9, CC12, CC15, ST49
CC1, CC30, ST34
CC45 agr IV, CC50
Bold figures; statistically significant
Presence of virulence genes.
|
|
|
|
|
|
|
|---|---|---|---|---|---|
|
| |||||
|
| capsular polysaccharide 5 | 8 (17) | 31 (35) | 2.6 (1.1-6.2) |
|
|
| capsular polysaccharide 8 | 38 (83) | 57 (66) | 0.39 (0.16-0.93) |
|
|
| polysaccharide intercellular adhesin | 46 (100) | 88 (100) | 1 | |
|
| |||||
|
| Bone sialoprotein-binding protein | 39 (85) | 79 (90) | 1.6 (0.55-4.55) | 0.41 |
|
| Clumping factors A and B | 46 (100) | 88 (100) | ||
|
| Collagen binding adhesin | 37 (80) | 43 (49) | 0.23 (0.10-0.54) |
|
|
| Cell wall associated fibronectin-binding protein | 44 (96) | 86 (98) | 2.0 (0.27-14) | 0.61 |
|
| Cell surface elastin-binding protein | 46 (100) | 88 (100) | 1 | |
|
| Enolase | 46 (100) | 88 (100) | 1 | |
|
| Fibrinogen binding protein | 46 (100) | 88 (100) | 1 | |
|
| Fibronectin-binding protein A | 46 (100) | 88 (100) | 1 | |
|
| Fibronectin-binding protein B | 27 (59) | 71 (81) | 2.9 (1.3-6.5) |
|
|
| Major hisocompatibility complex class II analog protein | 46 (100) | 87 (99) | 1.5 (1.4-1.7) | 1 |
|
|
| 8 (17) | 38 (43) | 3.6 (1.5-8.6) |
|
|
| Serine-aspartate repeat protein C | 46 (100) | 88 (100) | 1 | |
|
| Serine-aspartate repeat protein D | 40 (87) | 81 (92) | 1.7 (0.55-5.5) | 0.37 |
|
| Van Willebrand factor binding protein | 46 (100) | 88 (100) | 1 | |
|
| |||||
|
| |||||
|
| α-toxin | 46 (100) | 86 (98) | 0.55 | |
|
| β-toxin | 39 (85) | 71 (88) | 0.80 (0.30-2.1) | 0.81 |
|
| δ-toxin | 46 (100) | 88 (100) | 1 | |
| hl2 | Putative protein similar to hemolysin | 46 (100) | 87 (99) | 1 | |
|
| Channel protein, hemolysin III family protein | 45 (98) | 87 (99) | 1 | |
|
| |||||
|
| γ-toxin | 46 (100) | 88 (100) | 1 | |
|
| Panton-Valentine leukotoxin | 0 (0) | 1 (1) | 1 | |
|
| Leukocidin D, E component | 12 (26) | 46 (52) | 3.1 (1.4-6.8) |
|
|
| Leukocidin homologue family protein | 46 (100) | 88 (100) | 1 | |
|
| |||||
|
| Exfoliative toxin A | 3 (7) | 4 (5) | 0.69 | |
|
| Exfoliative toxin B | 0 (0) | 0 (0) | 1 | |
|
| Exfoliative toxin D | 3 (7) | 8 (9) | 0.75 | |
|
| |||||
| sea | Staphylococcal enterotoxin A | 10 (22) | 16 (18) | 0.80 (0.33-1.9) | 0.65 |
|
| Staphylococcal enterotoxin A, allele from N315 | 2 (4) | 12 (14) | 0.14 | |
|
| Staphylococcal enterotoxin B | 2 (4) | 7 (8) | 0.72 | |
|
| Staphylococcal enterotoxin C+L | 7 (15) | 12 (14) | 0.88 (0.32-2.4) | 0.80 |
|
| Staphylococcal enterotoxin D+J+R | 3 (7) | 9 (10) | 0.55 | |
|
| Staphylococcal enterotoxin E | 0 (0) | 0 (0) | 1 | |
|
| Staphylococcal enterotoxin G+I+M+N+O+U | 40 (87) | 61 (69) | 0.34 (0.128-0.89) |
|
|
| Staphylococcal enterotoxin H | 1 (2) | 4 (5) | 0.66 | |
|
| Staphylococcal enterotoxin K+Q | 0 (0) | 4 (5) | 0.30 | |
|
| Toxic shock syndrome toxin (TSST)-1 | 15 (33) | 15 (17) | 0.43 (0.19-0.97) | 0.050 |
|
| |||||
|
| Aureolysin | 46 (100) | 88 (100) | 1 | |
|
| Serine protease A, B | 12 (26) | 46 (55) | 3.4 (1.6-7.4) |
|
|
| Serine protease E | 29 (63) | 50 (57) | 0.77 (0.37-1.6) | 0.58 |
|
| Glutamyl endopeptidase | 46 (100) | 88 (100) | 1 | |
|
| Staphopain B, A | 46 (100) | 88 (100) | 1 | |
|
| Staphylokinase | 38 (83) | 73 (83) | 1.0 (0.40-2.6) | 1 |
|
| Chemotaxis inhibitory protein | 38 (83) | 69 (78) | 0.77 (0.31-1.9) | 0.65 |
|
| Staphylococcal complement inhibitor | 41 (89) | 86 (98) | 5.2 (0.98-28) |
|
|
| |||||
|
| Epidermal cell differentiation inhibitor | 0 (0) | 0 (0) | 1 | |
|
| Epidermal cell differentiation inhibitor B | 3 (7) | 8 (9) | 0.75 | |
|
| Staphylococcal exotoxin-like protein | 25 (56) | 70 (81) | 3.3 (1.5-7.3) |
|
| isdA | Transferrin binding protein | 46 (100) | 88 (100) | 1 |
Fisher’s exact test
Locus tag SACOL0921, GenBank CP000046.1: Position 927776-928816
Locus tag SACOL2160, GenBank CP000046.1: Position 2239231-2239914
Locus tag SACOL2004, GenBank CP000046.1: Position 2064956-2065972, Locus tag SACOL2006, GenBank CP000046.1: Position 2065994-2067049
Also known as enterotoxin sep
5 isolates belonging to CC50 showed a partial deletion of the locus egc-cluster missing seg
Locus tag SACOL1869, GenBank CP000046.1: Position 1920785-1921501
Locus tag SACOL1868, GenBank CP000046.1: Position 1919938-1920660
Locus tag SACOL1057, GenBank CP000046.1: Position 1063016-1064026
Locus tag SACOL1056, GenBank CP000046.1: Position 1061753-1062934
Locus tag SACOL1970, GenBank CP000046.1: Position 2034319-2035485
Locus tag SACOL0442, GenBank CP000046.1: Position 445958-446569. Two isolates with ambiguous results not included.
Bold figures; statistically significant
The distribution of genes encoding exopolysacharides, MSCRAMMs, exotoxins, enzymes and other miscellaneous genes are shown in Table 4.
Figure 1Distribution of genes associated with invasive disease or nasal carriage status in relation to CCs.
Black circle indicates that all isolates within the CC harbor the gene and white circle that none of the isolates does. A divided circle indicates variable gene presence within the CC. In most cases the presence of virulence genes was linked to CC affiliation.
Comparison between invasive non IE isolates and IE isolates in virulence genes associated with invasive disease.
|
|
|
|
|
|---|---|---|---|
|
| 5 (11) | 13 (24) | 13 (39) |
|
| 8 (17) | 16 (29) | 15 (45) |
|
| 27 (59) | 47 (85) | 24 (73) |
|
| 8 (17) | 18 (33) | 20 (61) |
|
| 12 (26) | 28 (51) | 20 (61) |
|
| 12 (26) | 28 (51) | 20 (61) |
|
| 25 (56) | 44 (80) | 26 (79) |